

# Clinical trials of antithrombotics for acute coronary syndrome in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 direct thrombin inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>bivalirudin vs eptifibatide + heparin</b>			
<b>PROTECT-TIMI 30 , 2006</b> [NCT00250471] n=284/573 follow-up: hospital stay	bivalirudin alone versus eptifibatide plus either unfractionated heparin or enoxaparin	non ST elevation ACS patients undergoing PCI	Parallel groups open International
<b>Argatroban vs heparin</b>			
<b>ARGAMI-2 , 1998</b> n=NA follow-up: 30 days	Argatroban 6020 mg/kg bolus; 24 g /kg/min infusion for 72h versus UFH 5000 IU bolus; 1000 IU/h infusion	AMI	
<b>bivalirudin vs heparin</b>			
<b>HERO , 1997</b> n=272/140 follow-up: 35 days	Bivalirudin 0.1250.250 mg/kg bolus; 0.1250.500 mg /kg/min infusion for 72h versus UFH 5000 IU bolus; 10001200 IU/h infusion	AMI (patients presenting within 12 hours with ST-segment elevation)	Parallel groups double blind
<b>BAT (Bittl) , 1995</b> n=2059/2039 follow-up: 6 months	Bivalirudin 1.0 mg/kg bolus; 2.5 mg /kg/h for 4 h, then 0.2 mg /kg/h infusion for 24h versus UFH 175 IU/kg bolus; 15 IU mg /kg/h infusion	patients undergoing angioplasty for unstable or postinfarction angina	Parallel groups double blind North America and Europe
<b>Efegatran vs heparin</b>			
<b>Klootwijk , 1999</b> n=432 follow-up: 30 days	Efegatran 0.10.3 mg/kg bolus; 0.1051.200 mg /kg/h infusion for 48h versus UFH 5000 IU bolus; 1000 IU/h infusion	patients with unstable angina	Parallel groups open
<b>Hirudin vs heparin</b>			
<b>OASIS , 1997</b> n=538/371 follow-up: 7 days	low-dose hirudin (0.2 mg/kg bolus+0.10 mg/kg/h infusion) or medium-dose hirudin (0.4 mg/kg bolus+0.15 mg/kg/h infusion) for 72h versus heparin 5000 IU bolus+1000 to 1200 U/h	patients with unstable angina or suspected acute MI without ST-segment elevation	Parallel groups open

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>HIT-4 , 1999</b> n=447 follow-up: 30 days	Hirudin 0.2 mg/kg bolus; 0.5 mg/kg twice daily 0.1 mg/kg 0.1 mg /kg/h infusion for 5-7 days versus Placebo bolus, UFH 12 500 IU twice daily	patients with AMI <=6 h were treated with aspirin and streptokinase	Parallel groups double blind
<b>TIMI 9B , 1996</b> n=3002 follow-up: 30 days	Hirudin 0.1 mg/kg bolus; 0.1 mg /kg/h infusion for 96h versus UFH 5000 IU bolus; 1000 IU/h infusion	Unstable angina or AMI	Parallel groups open
<b>GUSTO IIB , 1996</b> n=12142 follow-up: 30days (1 year)	Hirudin 0.1 mg/kg bolus; 0.1 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 1000 IU/h infusion for 72H	patients with acute coronary syndromes	Parallel groups open
<b>OASIS pilot , 1997</b> n=909 follow-up: 6 months	Hirudin 0.20.4 mg/kg bolus; 0.100.15 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 10001200 IU/h infusion	patients with unstable angina or suspected acute MI without ST-segment elevation	Parallel groups open
<b>OASIS 2 , 1999</b> n=5083/5058 follow-up: 7 days (6 months)	Hirudin 0.4 mg/kg bolus; 0.15 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 15 IU /kg/h infusion	patients with unstable angina or suspected acute myocardial infarction without ST elevation	Parallel groups double blind
<b>HELVETICA (Serruys) , 1995</b> n=1141 follow-up: 6 months	Hirudin 40 mg intravenous bolus; 0.2 mg /kg/h infusion for 24 h, then 40 mg or placebo twice daily for 72h versus UFH 10 000 IU bolus; 15 IU /kg/h infusion for 24 h, then placebo twice daily	patients with unstable angina who were scheduled for angioplasty	Parallel groups double blind
<b>Inogatran vs heparin</b>			
<b>TRIM , 1997</b> n=1209 follow-up: 30 days	Inogatran 0.15.5 mg bolus; 2.010.0 mg/h infusion for 72h versus UFH 5000 IU bolus; 1200 IU/h infusion	patients with suspected unstable angina, or non-Q wave myocardial infarction	Parallel groups double blind

## References

### PROTECT-TIMI 30, 2006:

Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. *J Am Coll Cardiol* 2006;47:2364-73 [[16781360](#)]

### ARGAMI-2, 1998:

Alderman EL Results from late-breaking clinical trials sessions at ACC '98. American College of Cardiology. *J Am Coll Cardiol* 1998;32:1-7 [[9669241](#)]

Rott D, Behar S, Hod H, Feinberg MS, Boyko V, Mandelzweig L, Kaplinsky E, Gottlieb S Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures. *Am Heart J* 2001;141:267-76 [[11174342](#)]

Behar S, Hod H, Kaplinsky E, et al. Argatroban versus heparin as adjuvant therapy for thrombolysis for acute myocardial infarction: safety considerations ARGAMI-2 study [abstract] *Circulation* 1998;98(1 Suppl):I453-4

**HERO, 1997:**

White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. *Circulation* 1997 Oct 7;96:2155-61 [9337184]

**BAT (Bittl), 1995:**

Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. *N Engl J Med* 1995 Sep 21;333:764-9 [7643883]

**Klootwijk, 1999:**

Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, Stibbe J, Muller EJ, Poortermans KJ, Deckers JW, Simoons ML Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. *Eur Heart J* 1999 Aug;20:1101-11 [10413640]

**OASIS, 1997:**

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. *Circulation* 1997 Aug 5;96:769-77 [9264481]

**HIT-4, 1999:**

Neuhaus KL, Molhoek GP, Zeymer U, Tebbe U, Wegscheider K, Schroder R, Camez A, Laarman GJ, Grollier GM, Lok DJ, Kuckuck H, Lazarus P Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. *J Am Coll Cardiol* 1999 Oct;34:966-73 [10520777]

**TIMI 9B, 1996:**

Antman EM Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. *Circulation* 1996 Sep 1;94:911-21 [8790025]

**GUSTO IIB, 1996:**

A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIB investigators. *N Engl J Med* 1996 Sep 12;335:775-82 [8778585]

**OASIS pilot, 1997:**

Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. *Lancet* 1999 Feb 6;353:429-38 [9989712]

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. *Circulation* 1997 Aug 5;96:769-77 [9264481]

**OASIS 2, 1999:**

Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. *Lancet* 1999;353:429-38 [9989712]

**HELVETICA (Serruys), 1995:**

Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. *N Engl J Med* 1995 Sep 21;333:757-63 [7643882]

**TRIM, 1997:**

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. *Eur Heart J* 1997;18:1416-25 [9458447]

## 2 long term LMWH

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>dalteparin vs placebo (on top of aspirin)</b>			
<b>FRIC prolonged treatment phase (LWMH vs PBO) , 1997</b> n=731/751 follow-up: 45 days	dalteparin SC 120 i.u./kg twice-daily for 6 days followed by dalteparin 7500UI daily up to day 45 (+aspirin) versus unfractionated heparin dose-adjusted intravenous infusion (for at least 48h) then by subcutaneous injection up to day 6 (then placebo) (+aspirin)	Patients with unstable angina or non-Q-wave myocardial infarction	Parallel groups double blind
<b>FRISC (long term) , 1996</b> n=746/760 follow-up: 40 days	dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin versus matched placebo + aspirin	patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours	Parallel groups double blind Sweden
<b>FRISC (short term) , 1996</b> n=746/760 follow-up: 6 days	dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin versus matched placebo + aspirin	patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours	double blind Sweden
<b>enoxaparin vs UFH (on top of aspirin)</b>			
<b>ESSENCE , 1997</b> n=1607/1564 follow-up: 14 days (30 days)	enoxaparin 1mg/kg, twice daily during 48h-8days versus continuous intravenous unfractionated heparin	patients with angina at rest or nonQ-wave myocardial infarction	Parallel groups Double blind United states, Canada, South America, Europe
<b>INTERACT , 2006</b> n=380/366 follow-up: 30 days (2.5y)	enoxaparin (1 mg/kg subcutaneously twice daily) for 48 hours (+eptifibatide and aspirin) versus intravenous UFH (70 U/kg bolus followed by 15 U/kg per hour adjusted to an activated partial thromboplastin time of 1.5-2 times control) for 48 hours (+eptifibatide and aspirin)	high-risk patients with ACS receiving aspirin and eptifibatide	Parallel groups open Canada
<b>SYNERGY , 2005</b> [NCT00043784] n=4993/4985 follow-up: 30 days	Enoxaparin 1 mg/kg twice daily versus unfractionated heparin	high-risk patients with acute coronary syndromes	Parallel groups open 12 countries
<b>TIMI 11 B (long term) , 1998</b> n=1953/1957 follow-up: 43 days	enoxaparin during both the acute phase (IV) and outpatient phase (SC) versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections)	unstable angina/nonQ-wave myocardial infarction	double blind North America, South America,

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>TIMI 11 B (short term) , 1998</b> n=1953/1957 follow-up: 8 days (43 days)	enoxaprin during both the acute phase and outpatient phase versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections)	unstable angina/nonQ-wave myocardial infarction	Parallel groups double blind North America, South America,
<b>nadroparin vs UFH (on top of aspirin)</b>			
<b>FRAXIS (14 days) , 1998</b> n=1151/1151 follow-up: 14 days	nadroparin for 14 days versus unfractionated heparin for 14 days	unstable angina or non-Q wave myocardial infraction	double blind 17 countries
<b>FRAXIS (6days) , 1998</b> n=1166/1151 follow-up: 14 days	nadroparin for 6 days (+aspirin) versus unfractionated heparin for 6 days (+aspirin)	unstable angina or non-Q wave myocardial infraction	Parallel groups Double blind 17 countries

## References

### **FRIC prolonged treatment phase (LWMH vs PBO), 1997:**

Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olausson E, Undeland S, Ludwig K Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) *Circulation* 1997 Jul 1;96:61-8 [9236418]

### **FRISC (long term), 1996:**

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. *Lancet* 1996;347:561-8 [8596317]

### **FRISC (short term), 1996:**

### **ESSENCE, 1997:**

Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmureur J, Bigonzi F A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. *N Engl J Med* 1997;337:447-52 [9250846]

### **INTERACT, 2006:**

Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. *Am Heart J* 2006;151:373-9 [16442903]

Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. *Circulation* 2003;107:238-44 [12538422]

### **SYNERGY, 2005:**

Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ 3rd, Califf RM High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. *JAMA* 2005 Nov 23;294:2594-600 [16304073]

White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. *Am Heart J* 2006;152:1042-50 [17161049]

Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hoc Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54 [15238590]

**TIMI 11 B (long term), 1998:**

**TIMI 11 B (short term), 1998:**

Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999 Oct 12;100:1593-601 [10517729]

**FRAXIS (14 days), 1998:**

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-62 [10529323]

**FRAXIS (6days), 1998:**

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-62 [10529323]

### 3 oral anticoagulant

6

Trial	Treatments	Patients	Trials design and methods
<b>coumadin vs control (on top of aspirin)</b>			
ASPECT-2 (coumadin+asp vs asp) , 2002 n=333/336 follow-up: 1 year	coumadin(INR mean 2.4) +aspirin versus aspirin	UA, AMI	open the Netherlands
<b>warfarin vs control (on top of aspirin)</b>			
ATACS (pilot study) (warfarin vs control) , 1990 n=37/32 follow-up: 65279;3 months	heparin/warfarin target INR 65279;3-4.5 + aspirin versus aspirin alone	65279;UA, NSTEMI	open
ATACS , 1994 n=105/109 follow-up: 3 months	heparin/warfarin (INR median 2.3) + aspirin versus aspirin	UA, NSTEMI	open
CARS , 1997 n=5410/3393 follow-up: 14 months	warfarin (INR mean 1.5) (3 mg warfarin or 1 mg warfarin with 80 mg aspirin) versus aspirin 160 mg/d	AMI	
OASIS Pilot (phase 1) , 1998 n=155/154 follow-up: 6 months	warfarin 3mg/d for 6 months (INR mean 1.5) versus control	UA, NSTEMI	open
OASIS Pilot (phase 2) , 1998 n=98/99 follow-up: 3 months	warfarin adjusted dose (INR mean 2.3) for 3 months versus standard treatment	UA, NSTEMI	open

continued...

Trial	Treatments	Patients	Trials design and methods
<b>OASIS-2 Warfarin Substudy , 2001</b> n=1848/1864 follow-up: 5 months	warfarin target INR 65279;22.5 for 5 months +aspirin versus control	UA	open
<b>APRICOT-2 , 2002</b> n=135/139 follow-up: 3 months	moderate-intensity coumarin target INR 2-3 (+aspirin) versus aspirin	STEMI	
<b>CHAMP , 2002</b> n=2522/2537 follow-up: 2.7 years	-	AMI	
<b>WARIS , 2002</b> n=1208/1206 follow-up: 4 years	-	AMI	
<b>LoWASA , 2004</b> n=1659/1641 follow-up: 5 years	-	AMI	
<b>Zibaenezhad , 2004</b> n=70/70 follow-up: 1 year	-	AMI	
<b>warfarin vs placebo (on top of aspirin)</b>			
<b>Williams , 1997</b> n=29/28 follow-up: 2.5 months	warfarin target INR 65279;22.5 +aspirin versus placebo +aspirin	UA, AMI	double blind
<b>Huyhn , 2001</b> n=44/46 follow-up: 1 year	warfarin adjusted dose for INR 22.5 +aspirin versus placebo +aspirin	UA, NSTEMI with prior CABG	double blind
<b>coumadin vs aspirin</b>			
<b>ASPECT-2 (coumadin vs aspirin) , 2002</b> n=325/336 follow-up: 1 year (range 0-26 months)	coumadin (phenprocoumon or acenocoumarol) target INR 3-4) versus aspirin 80mg daily	UA, AMI	Parallel groups open the Netherlands
<b>warfarin vs aspirin</b>			
<b>ATACS (pilot study) warfarin vs aspirin , 1990</b> n=24/32 follow-up: 65279;3 months	heparin/warfarin target INR 65279;3-4 versus aspirin 65279;325 mg daily	65279;UA, NSTEMI	open

## References

### ASPECT-2 (coumadin+asp vs asp), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13 [12126819]

### ATACS (pilot study) (warfarin vs control), 1990:

Cohen M, Adams PC, Hawkins L, Bach M, Fuster V Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). *Am J Cardiol* 1990;66:1287-92 [[2244556](#)]

**ATACS, 1994:**

Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KA, Chesebro JH, Strain J, Keller C Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. *Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation* 1994;89:81-8 [[8281698](#)]

**CARS, 1997:**

Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. *Lancet* 1997;350:389-96 [[9259652](#)]

**OASIS Pilot (phase 1), 1998:**

Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. *Circulation* 1998;98:1064-70 [[9736592](#)]

**OASIS Pilot (phase 2), 1998:**

Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. *Circulation* 1998;98:1064-70 [[9736592](#)]

**OASIS-2 Warfarin Substudy, 2001:**

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. *J Am Coll Cardiol* 2001;37:475-84 [[11216966](#)]

**APRICOT-2, 2002:**

Brouwer MA, van den Bergh PJ, Aengevaeren WR, Veen G, Luijten HE, Hertzberger DP, van Boven AJ, Vromans RP, Uijen GJ, Verheugt FW Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. *Circulation* 2002;106:659-65 [[12163424](#)]

**CHAMP, 2002:**

Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. *Circulation* 2002;105:557-63 [[11827919](#)]

**WARIS, 2002:**

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med* 2002;347:969-74 [[12324552](#)]

**LoWASA, 2004:**

Herlitz J, Holm J, Peterson M, Karlson BW, Haglid Evander M, Erhardt L Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. *Eur Heart J* 2004;25:232-9 [[14972424](#)]

**Zibaenezhad, 2004:**

Zibaenezhad MJ, Mowla A, Sorbi MH Warfarin and aspirin versus aspirin alone in patients with acute myocardial infarction: a pilot study. *Angiology* 2004;55:17-20 [[14759085](#)]

**Williams, 1997:**

Williams MJ, Morison IM, Parker JH, Stewart RA Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. *J Am Coll Cardiol* 1997;30:364-9 [[9247506](#)]

**Huyhn, 2001:**

Huyhn T, Throux P, Bogaty P, Nasmith J, Solymoss S Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. *Circulation* 2001;103:3069-74 [[11425770](#)]

**ASPECT-2 (coumadin vs aspirin), 2002:**

**ATACS (pilot study) warfarin vs aspirin, 1990:**



Cohen M, Adams PC, Hawkins L, Bach M, Fuster V Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol 1990;66:1287-92 [2244556]

## 4 oral factor Xa inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>apixaban vs placebo</b>			
<b>APPRAISE 2 , 2011</b> [NCT00831441] n=3705/3687 follow-up: 8 months	apixaban 5mg twice daily versus placebo	patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events	Parallel groups double blind 39 countries
<b>APPRAISE-1 (10mg od) , 2009</b> [NCT00313300] n=318/611 follow-up: 6 months	apixaban 10 mg once daily versus placebo	patients with a recent ST-elevation or nonST-elevation acute coronary syndrome(<7 days)	Parallel groups double blind Europe, Middle East, North America
<b>APPRAISE-1 (2.5 mg bid) , 2009</b> [NCT00313300 ] n=NA follow-up: 6 months	Apixaban 2.5mg twice daily versus placebo	patients with a recent ST-elevation or nonST-elevation acute coronary syndrome(<7 days)	double blind Europe, Middle East, North America
<b>APPRAISE japan ongoing</b> [NCT00852397] n=NA follow-up:	2 doses of apixaban (2.5 mg BID and 5.0 mg BID) for 24 weeks in combination with standard therapy (aspirin and /or additional antiplatelet therapy) versus placebo	patients with recent (<=7 days) acute coronary syndrome	double-blind Japan
<b>rivaroxaban 2.5mg vs placebo</b>			
<b>ATLAS ACS 2 - TIMI 51 (2.5mg) , 2011</b> [NCT00809965] n=5174/5176 follow-up: 13 months	rivaroxaban 2.5 mg twice daily in addition to standard care versus placebo	patients with a recent ACS	Parallel groups double blind 44 countries
<b>rivaroxaban 5mg vs placebo</b>			
<b>ATLAS ACS 2 - TIMI 51 (5mg) , 2011</b> [NCT00809965] n=5176/5176 follow-up: 13 months	rivaroxaban 5 mg twice daily in addition to standard care versus placebo	patients with a recent ACS	double blind 44 countries
<b>ximelagatran vs placebo</b>			
<b>ESTEEM , 2003</b> n=1245/638 follow-up: 6 months	oral ximelagatran at doses of 24 mg, 36 mg, 48 mg, or 60 mg twice daily versus placebo	patients who had had recent ST-elevation or non-STelevation myocardial infarction	Parallel groups double-blind
<b>otamixaban vs unfractionated heparin</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>SEPIA-ACS1 TIMI 42 , 2009</b> [NCT00317395] n=2792/449 follow-up: 7 days	otamixaban 5 doses (008 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) versus Heparin+eptifibatide	patients with non-ST-elevation acute coronary syndromes	Parallel groups double blind 36 countries

## References

### APPRAISE 2, 2011:

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011 Jul 24;: [21780946] 10.1056/NEJMoa1105819

### APPRAISE-1 (10mg od), 2009:

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 2009;: [19470889]

### APPRAISE-1 (2.5 mg bid), 2009:

### APPRAISE japan, :

### ATLAS ACS 2 - TIMI 51 (2.5mg), 2011:

### ATLAS ACS 2 - TIMI 51 (5mg), 2011:

### ESTEEM, 2003:

### SEPIA-ACS1 TIMI 42, 2009:

10

## 5 P2Y12 receptor antagonist

Trial	Treatments	Patients	Trials design and methods
<b>ticagrelor vs clopidogrel</b>			
<b>PLATO , 2009</b> [NCT00391872] n=9333/9291 follow-up: 1 y	ticagrelor 90mg twice daily versus clopidogrel 75mg once daily	patients with an acute coronary syndrome, with or without ST-segment elevation (onset of symptoms within the previous 24h).	Parallel groups double blind 43 countries
<b>DISPERSE-2 (90mg) , 2007</b> n=334/327 follow-up: 12 weeks	ticagrelor 90 mg twice daily versus clopidogrel	patients with NSTEMI-ACS, treated with aspirin and standard therapy for ACS	Parallel groups double blind

## References

### PLATO, 2009:

### DISPERSE-2 (90mg), 2007:

## 6 PAR-1 inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>atopaxar vs placebo</b>			
<b>LANCELOT ACS</b> n=603 follow-up:	400-mg loading dose of atopaxar followed by a daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks versus placebo	unstable-angina or non-STEMI patients	Parallel groups
<b>J-LANCELOT , 2010</b> n=NA follow-up:	atopaxar at a loading dose of 400 mg followed by 50 mg per day, 100 mg per day, or 200 mg per day for 12 weeks versus atopaxar at a loading dose of 400 mg followed by placebo	patients with acute coronary syndrome (unstable angina and NSTEMI)	Parallel groups Japan

## References

LANCELOT ACS, :  
J-LANCELOT, 2010:

11

## 7 platelet aggregation inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>triflusal vs aspirin</b>			
<b>TIM , 2000</b> n=1135/1140 follow-up: 35 days	triflusal 600 mg daily versus aspirine 300 mg daily	AMI within less than 24 h of symptom onsete	Parallel groups double blind Portugal, Spain, Italy
<b>aspirin vs control</b>			
<b>ATACS-pilot , 1990</b> n=37/24 follow-up: 3m	Aspirin 80mg/d (Heparin + Warfarin) versus full-dose heparin followed by warfarin	acute coronary syndromes	
<b>aspirin vs placebo</b>			
<b>VA-main , 1983</b> n=661/677 follow-up: 3m	Aspirin 324mg/d versus placebo	men with unstable angina	double blind
<b>Canadian (Aspirin vs PBO) , 1985</b> n=NA follow-up: 18m	Aspirin 1300mg/d versus placebo	patients with unstable angina	double blind

continued...

Trial	Treatments	Patients	Trials design and methods
<b>VA-pilot</b> <i>unpublished</i> n=26/24 follow-up: 3m	-	-	
<b>RISC</b> , 1990 n=474/471 follow-up: 12m	Aspirin 75mg/d versus placebo	men with unstable coronary artery disease (unstable angina or non-Q wave myocardial infarction	Factorial plan double blind Sweden
<b>ALDUSA-pilot</b> <i>unpublished</i> n=56/28 follow-up: 12m	-	-	
<b>Throux</b> , 1988 n=121/118 follow-up: 6d (3m)	Aspirin 325 mg twice daily versus placebo	acute unstable angina	double blind
<b>aspirin + dipyridamol vs placebo</b>			
<b>Prandoni</b> , 1991 n=44/44 follow-up: 12m	Aspirin 50mg/d + Dipyridamol 400mg/d versus placebo	patients with acute unstable angina	double blind
<b>aspirin + sulfinpyrazone vs placebo</b>			
<b>Canadian (Aspirin + sulfinpyrazone)</b> , 1985 n=416/139 follow-up: 18m	Aspirin 1300mg/d + sulfinpyrazone 800mg/d versus placebo	patients with unstable angina	double blind
<b>sulfinpyrazone vs placebo</b>			
<b>Canadian (sulfinpyrazone alone)</b> , 1985 n=NA follow-up: 18m	sulfinpyrazone 800mg/d versus placebo	patients with unstable angina	double blind
<b>trapidil vs placebo</b>			
<b>Modena</b> <i>unpublished</i> n=71/73 follow-up: 6m	-	-	
<b>trifusal vs placebo</b>			
<b>Plaza</b> , 1993 n=143/138 follow-up: 6m	trifusal 300 mg three times daily versus placebo	patients with unstable angina	Parallel groups double blind Spain
<b>ASA high dose vs ASA low dose</b>			
<b>CURRENT - OASIS 7 (ASA)</b> , 2010 [NCT00335452] n=12507/12579 follow-up: 30 days	High-dose aspirin versus Low-dose aspirin	ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization)	Factorial plan open
<b>prasugrel vs clopidogrel</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>TRILOGY ACS (overall population) , 2012</b> [NCT00699998] n=4663/4663 follow-up: 17 months (median)	prasugrel 10 mg daily versus clopidogrel 75 mg daily	patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index event	Parallel groups double-blind 52 countries
<b>TRITON-TIMI 38 , 2007</b> [NCT00097591] n=6813/6795 follow-up:	prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months versus clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months	patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention	Parallel groups double blind 30 countries
<b>ACAPULCO</b> <i>ongoing</i> n=NA	-	-	

## References

TIM, 2000:  
 ATACS-pilot, 1990:  
 VA-main, 1983:  
 Canadian (Aspirin vs PBO), 1985:  
 VA-pilot, 0:  
 RISC, 1990:  
 ALDUSA-pilot, 0:  
 Throux, 1988:  
 Prandoni, 1991:  
 Canadian (Aspirin + sulfinpyrazone), 1985:  
 Canadian (sulfinpyrazone alone), 1985:  
 Modena, 0:  
 Plaza, 1993:  
 CURRENT - OASIS 7 (ASA), 2010:  
 TRILOGY ACS (overall population), 2012:  
 TRITON-TIMI 38, 2007:  
 ACAPULCO, :

## 8 selective PAR-1 thrombin receptor antagonist

Trial	Treatments	Patients	Trials design and methods
<b>vorapaxar vs placebo (on top standard therapy)</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>TRACER , 2011</b> [NCT00527943] n=NA follow-up:	vorapaxar (SCH 530348) oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year versus Placebo (added to the existing standard of care (eg, aspirin, clopidogrel)	patients with acute coronary syndrome	Parallel groups double-blind

## References

TRACER, 2011:

## 9 short term LMWH

Trial	Treatments	Patients	Trials design and methods
<b>dalteparin vs placebo (on top of aspirin)</b>			
<b>FRIC prolonged treatment phase (LWMH vs PBO) , 1997</b> n=731/751 follow-up: 45 days	dalteparin SC 120 i.u./kg twice-daily for 6 days followed by dalteparin 7500UI daily up to day 45 (+aspirin) versus unfractionated heparin dose-adjusted intravenous infusion (for at least 48h) then by subcutaneous injection up to day 6 (then placebo) (+aspirin)	Patients with unstable angina or non-Q-wave myocardial infarction	Parallel groups double blind
<b>FRISC (long term) , 1996</b> n=746/760 follow-up: 40 days	dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin versus matched placebo + aspirin	patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours	Parallel groups double blind Sweden
<b>FRISC (short term) , 1996</b> n=746/760 follow-up: 6 days	dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin versus matched placebo + aspirin	patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours	double blind Sweden
<b>LMWH vs placebo (on top of aspirin)</b>			
<b>Gurfinkel (LMWH+asp vs asp) , 1995</b> n=68/73 follow-up: 5-7 days	aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin (200 mg/day)	patients with unstable angina	Parallel groups single blind
<b>enoxaparin vs unfractionated heparin</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>RESCUE</b> [NCT00077818] n=NA follow-up: 30 days	Enoxaparin versus unfractionated heparin	patients diagnosed with acute coronary syndrome in the emergency department	Parallel groups open
<b>enoxaparin vs tinzaparin</b>			
<b>EVET , 2005</b> n=220/218 follow-up: 30 days	enoxaparin, 100 IU/kg subcutaneously twice daily +aspirin for 7 days versus tinzaparin, 175 IU/kg subcutaneously once daily +aspirin for 7 days	patients with non-ST-segment elevation acute coronary syndromes	Parallel groups open
<b>dalteparin vs UFH (on top of aspirin)</b>			
<b>FRIC (acute phase LMWH vs UFH) , 1997</b> n=751/731 follow-up: 6 days	twice-daily weight-adjusted subcutaneous injections of dalteparin (120 i.u./kg) (+aspirin) versus dose-adjusted intravenous infusion of unfractionated heparin (+aspirin)	Patients with unstable angina or non-Q-wave myocardial infarction	open
<b>enoxaparin vs UFH (on top of aspirin)</b>			
<b>ESSENCE , 1997</b> n=1607/1564 follow-up: 14 days (30 days)	enoxaparin 1mg/kg, twice daily during 48h-8days versus continuous intravenous unfractionated heparin	patients with angina at rest or nonQ-wave myocardial infarction	Parallel groups Double blind United states, Canada, South America, Europe
<b>INTERACT , 2006</b> n=380/366 follow-up: 30 days (2.5y)	enoxaparin (1 mg/kg subcutaneously twice daily) for 48 hours (+eptifibatide and aspirin) versus intravenous UFH (70 U/kg bolus followed by 15 U/kg per hour adjusted to an activated partial thromboplastin time of 1.5-2 times control) for 48 hours (+eptifibatide and aspirin)	high-risk patients with ACS receiving aspirin and eptifibatide	Parallel groups open Canada
<b>SYNERGY , 2005</b> [NCT00043784] n=4993/4985 follow-up: 30 days	Enoxaparin 1 mg/kg twice daily versus unfractionated heparin	high-risk patients with acute coronary syndromes	Parallel groups open 12 countries
<b>TIMI 11 B (long term) , 1998</b> n=1953/1957 follow-up: 43 days	enoxaparin during both the acute phase (IV) and outpatient phase (SC) versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections)	unstable angina/nonQ-wave myocardial infarction	double blind North America, South America,
<b>TIMI 11 B (short term) , 1998</b> n=1953/1957 follow-up: 8 days (43 days)	enoxaparin during both the acute phase and outpatient phase versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections)	unstable angina/nonQ-wave myocardial infarction	Parallel groups double blind North America, South America,

continued...

Trial	Treatments	Patients	Trials design and methods
<b>LMWH vs UFH (on top of aspirin)</b>			
Gurfinkel (LMWH+asp vs UFH+asp) , 1995 n=68/70 follow-up: 5-7 days	aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin plus regular heparin (400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time	patients with unstable angina	Parallel groups single blind
<b>nadroparin vs UFH (on top of aspirin)</b>			
FRAXIS (14 days) , 1998 n=1151/1151 follow-up: 14 days	nadroparin for 14 days versus unfractionated heparin for 14 days	unstable angina or non-Q wave myocardial infraction	double blind 17 countries
FRAXIS (6days) , 1998 n=1166/1151 follow-up: 14 days	nadroparin for 6 days (+aspirin) versus unfractionated heparin for 6 days (+aspirin)	unstable angina or non-Q wave myocardial infraction	Parallel groups Double blind 17 countries

## References

FRIC prolonged treatment phase (LWMH vs PBO), 1997:

FRISC (long term), 1996:

FRISC (short term), 1996:

Gurfinkel (LMWH+asp vs asp), 1995:

RESCUE, :

EVET, 2005:

FRIC (acute phase LMWH vs UFH), 1997:

ESSENCE, 1997:

INTERACT, 2006:

SYNERGY, 2005:

TIMI 11 B (long term), 1998:

TIMI 11 B (short term), 1998:

Gurfinkel (LMWH+asp vs UFH+asp), 1995:

FRAXIS (14 days), 1998:

FRAXIS (6days), 1998:

## 10 short term UFH

Trial	Treatments	Patients	Trials design and methods
<b>UFH vs control (on top of aspirin)</b>			

continued...



<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Holdright , 1994 n=154/131 follow-up: hospital stay	intravenous heparin plus oral aspirin (150 mg once daily) versus aspirin alone 150 mg/d	unstable angina	Parallel groups single blind
RISC (heparin+aspirin vs ASP) , 1990 n=210/189 follow-up: 90 days	5 days of intermittent intravenous heparin + oral aspirin 75 mg/day versus oral aspirin 75 mg/day	unstable angina or non-Q-wave myocardial infarction	Parallel groups open
Theroux (heparin+ASP vs ASP) , 1988 n=122/121 follow-up: 3-9 days	aspirin 325 mg/d + heparin 1000 UI/hr IV versus aspirin 325 mg/d		double blind
<b>UFH, warfarin vs control (on top of aspirin)</b>			
ATACS (Cohen) , 1994 n=105/109 follow-up: 12 weeks	aspirin 162.5 mg daily plus heparin (activated partial thromboplastin time, two times control) followed by aspirin 162.5 mg daily plus warfarin (international normalized ratio, 2 to 3) for 12 weeks. versus aspirin alone (162.5 mg daily) for 12 weeks.	patients with unstable rest angina or non-Q-wave myocardial infarction with last episode of pain within 48 hours of randomization and who were nonprior aspirin users	Parallel groups single blind
Cohen (ATACS pilot) (heparin+aspirin vs asp) , 1990 n=37/32 follow-up: 12 weeks	aspirin (80 mg/day) plus heparin and then warfarin versus aspirin (325 mg/day)	Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening.	Parallel groups open
<b>UFH vs placebo</b>			
RISC (heparin vs PBO) , 1990 n=198/199 follow-up: 1y (5,30 and 90 days)	5 days of intermittent intravenous heparin versus placebo	men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction)	Factorial plan Sweden
Theroux (heparin vs PBO) , 1988 n=118/118 follow-up: 3-9 days	heparin (1000 units per hour by intravenous infusion) versus placebo	patients with acute unstable angina pectoris	double blind
<b>UFH + aspirin vs placebo</b>			
RISC (ASP+ heparin vs PBO) , 1990 n=210/199 follow-up: 1y (5,30 and 90 days)	oral aspirin 75mg/d + intermittent IV heparin 10000UI/d followed by 7500 UI 6-hourly for 4 days versus placebo	men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction)	Sweden
Theroux (heparin+aspirin vs PBO) , 1988 n=122/118 follow-up: 3-9 days	heparin (1000 units per hour by intravenous infusion)+ aspirin (325 mg twice daily) versus aspirin (325 mg twice daily)	-	double blind

continued...

Trial	Treatments	Patients	Trials design and methods
<b>UFH vs placebo (on top of aspirin)</b>			
Gurfinkel (UFH+aspirin vs aspirin) , 1995 n=70/73 follow-up: 5-7 days	aspirin plus UFH 5000 IU iv then 400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time versus aspirin 200 mg/day	patients greater than 21 years with unstable angina within 24 hours of randomization	Parallel groups double blind
<b>UFH, warfarin vs aspirin</b>			
Cohen (ATACS pilot) (heparin vs asp) , 1990 n=24/32 follow-up: 12 weeks	heparin followed by warfarin (without aspirin) versus aspirin 325 mg/day	Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening	Parallel groups open

## References

Holdright, 1994:

RISC (heparin+aspirin vs ASP), 1990:

Theroux (heparin+ASP vs ASP), 1988:

ATACS (Cohen), 1994:

Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990:

RISC (heparin vs PBO), 1990:

Theroux (heparin vs PBO), 1988:

RISC (ASP+ heparin vs PBO), 1990:

Theroux (heparin+aspirin vs PBO), 1988:

Gurfinkel (UFH+aspirin vs aspirin), 1995:

Cohen (ATACS pilot) (heparin vs asp), 1990:

## 11 synthetic oligosaccharide

Trial	Treatments	Patients	Trials design and methods
<b>fondaparinux vs enoxaparin</b>			
OASIS 5 , 2006 [NCT00139815] n=10057/10021 follow-up: 9 days (180 days)	fondaparinux 2.5 mg daily until hospital discharge or for up to eight days versus enoxaparin 1 mg per kilogram of body weight twice daily for two to eight days or until the patient was in clinically stable condition	patients with acute coronary syndromes	Parallel groups double blind 41 countries
PENTUA , 2004 n=908/230 follow-up: 9 days	Four doses fondaparinux (2.5, 4, 8, or 12 mg once daily) for three to seven days versus enoxaparin (1 mg/kg twice daily) for three to seven days	patients with ACS without persistent ST-segment elevation	

## References

OASIS 5, 2006:

PENTUA, 2004:

## 12 thienopyridine

Trial	Treatments	Patients	Trials design and methods
<b>ticlopidine vs control</b>			
STAI , 1990 n=314/338 follow-up: 6m	ticlopidine 250 mg b.i.d versus untreated control	patients with unstable angina <=48hrs from the pain onset	single blind
<b>ticlopidine vs placebo</b>			
Florida UA <i>unpublished</i> n=12/12 follow-up: 14d	-	-	
<b>clopidogrel + aspirin vs aspirin</b>			
CURE , 2001 n=6259/6303 follow-up: NA (median <9 months)	clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months versus aspirin (+placebo)	acute coronary syndromes without ST-segment elevation within 24 hours after the onset of symptoms	Parallel groups double blind 28 countries
<b>prasugrel vs clopidogrel</b>			
TRILOGY ACS (overall population) , 2012 [NCT00699998] n=4663/4663 follow-up: 17 months (median)	prasugrel 10 mg daily versus clopidogrel 75 mg daily	patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index event	Parallel groups double-blind 52 countries
TRITON-TIMI 38 , 2007 [NCT00097591] n=6813/6795 follow-up:	prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months versus clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months	patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention	Parallel groups double blind 30 countries
ACAPULCO <i>ongoing</i> n=NA	-	-	
<b>clopidogrel high-dose regimen vs clopidogrel standard-dose</b>			
CURRENT OASIS 7 (clopidogrel) , 2010 [NCT00335452] n=12520/12566 follow-up: 30 days	Double-dose clopidogrel versus Standard-dose clopidogrel	ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization)	Factorial plan open

## References

**STAI, 1990:**

**Florida UA, 0:**

**CURE, 2001:**

**TRILOGY ACS (overall population), 2012:**

**TRITON-TIMI 38, 2007:**

**ACAPULCO, :**

**CURRENT OASIS 7 (clopidogrel), 2010:**

## 13 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.